Adenocarcinoma primario de pulmón con morfología entérica asociado a un adenocarcinoma primario de colon

Hammoumi, Mohammed-Massine El; Ochi, Reda El; Kabiri, El Hassane

doi:10.1016/j.arbres.2015.05.012

Cited by 6 publications

(4 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, an increasing interest has been addressed by both pathologists and clinicians towards this NSCLC variant, as proved by the numerous cases described in the last 3 years (Refs 11, 12, 19, 20, 23, 24, 25, 26). At present, there is the lack of consensus about the diagnostic criteria to be employed, making the differential diagnosis between PAED and MCC often complicated and mainly based on the exclusion of synchronous or metachronous gastrointestinal malignancies (Refs 8, 17, 18, 20, 21, 29, 30).…”

Section: Discussionmentioning

confidence: 99%

“…As previously described, primary PAED diagnosis can be endorsed by excluding gastrointestinal malignancies through colonoscopy, CT or PET-CT scans (Refs 13, 14, 15, 18, 28). IHC and molecular diagnostics are emerging as promising and more specific tools to formulate the differential diagnosis, whereas the occurrence of both PAED and synchronous or metachronous colorectal cancer is uncommon, although still possible (Refs 8, 17, 29, 30).…”

Section: Pathogenesis and Clinical Featuresmentioning

confidence: 99%

“…Most studies were single-case reports or small patient series (Refs 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 16, 17, 21, 22, 29, 30, 31, 32, 34, 35, 36, 37, 38, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61) whereas sporadic cases were also described within larger studies on lung cancer, from which it was not always possible to retrieve demographic and clinical information (Refs 62, 63, 64, 65).…”

Section: Analysis Of Literature Datamentioning

confidence: 99%

“…An international panel of thoracic surgeons, oncologists, pneumologists, pathologists and radiologists representing the three scientific societies established that this pathological entity could be defined by an entero-like morphology in more than 50% of tumour cells, together with the positive IHC staining for at least one of the major markers of intestinal differentiation, namely cytokeratin 20 (CK20), Caudal Type Homeobox (CDX2) and/or Mucin 2 (MUC2) (Refs 14, 15). The positive staining for Cytokeratin 7 (CK7) and Thyroid Transcription Factor-1 (TTF-1) in approximately half cases also favours the differential diagnosis (Refs 13, 14, 15, 16, 17).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Pulmonary enteric adenocarcinoma: an overview

Palmirotta

Lovero

D’Oronzo

et al. 2020

Expert Rev. Mol. Med.

View full text Add to dashboard Cite

Most commonly described as sporadic, pulmonary adenocarcinoma with enteric differentiation (PAED) is a rare variant of invasive lung cancer recently established and recognised by the World Health Organization. This tumour is highly heterogeneous and shares several morphological features with pulmonary and colorectal adenocarcinomas. Our objective is to summarise current research on PAED, focusing on its immunohistochemical and molecular features as potential tools for differential diagnosis from colorectal cancer, as well as prognosis definition and therapeutic choice. PAED exhibits an ‘entero-like’ pathological morphology in more than half cases, expressing at least one of the typical immunohistochemical markers of enteric differentiation, namely CDX2, CK20 or MUC2. For this reason, this malignancy appears often indistinguishable from a colorectal cancer metastasis, making the differential diagnosis laborious. Although standard diagnostic criteria have not been established yet, in the past few years, a number of approaches have been addressed, aimed at defining specific immunohistochemical and molecular signatures. Based on previously published literature, we have collected and analysed molecular and immunohistochemical data on this rare neoplasm, and have described the state of the art on diagnostic criteria as well as major clinical and therapeutic implications. The analysis of data from 295 patients from 58 published articles allowed us to identify the most represented immunohistochemical and molecular markers, as well as major differences between Asian PAEDs and those diagnosed in European/North American countries. The innovative molecular approaches, exploring driver mutations or new gene alterations, could help to identify rare prognostic factors and guide future tailored therapeutic approaches to this rare neoplasm.

show abstract